PharmaEssentia revenue and financials
$1,175.00Change from previous close: −1.26%Absolute change: −$15.00
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 6,855 | 5,121 | 4,881 | — | 3,602 | 3,257 |
| Cost of revenue | 395 | 621 | 544 | — | 450 | 363 |
| Gross profit | 6,460 | 4,500 | 4,338 | — | 3,152 | 2,895 |
| Selling, general and administrative | 2,238 | 1,556 | 1,769 | — | 1,228 | 1,042 |
| Research and development | 1,067 | 857 | 1,007 | — | 829 | 747 |
| Operating income | 3,155 | 2,087 | 1,561 | — | 1,096 | 1,105 |
| EBIT | 3,205 | 2,340 | 2,018 | — | 105 | 1,466 |
| EBITDA | 3,328 | 2,457 | 2,123 | — | 203 | 1,563 |
| Interest expense | 6.0 | 4.7 | 5.8 | — | 8.8 | 5.4 |
| Pre-tax income | 3,199 | 2,336 | 2,013 | — | 95.8 | 1,460 |
| Income tax | 669 | 186 | 536 | — | -736 | 197 |
| Net income | 2,530 | 2,150 | 1,476 | — | 832 | 1,264 |
| Net income to common shareholders | 2,530 | 2,150 | 1,476 | — | 832 | 1,264 |
| Basic EPS | 5.53 | 5.22 | — | 3.60 | 1.83 | 3.08 |
| Diluted EPS | 5.53 | 5.21 | — | 3.58 | 1.82 | 3.07 |
| Average shares (basic) | 458 | 412 | — | 410 | 455 | 409 |
| Average shares (diluted) | 458 | 413 | — | 412 | 457 | 411 |